ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation : The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC).

/pdf/2015-esc-guidelines-for-the-management-of-acute-coronary-6did6h5nxk.pdf

2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC)

2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC)

/pdf/2017-esc-guidelines-for-the-management-of-acute-myocardial-14hhjrfylv.pdf

2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC).

99mTc
: technetium-99m
201TI
: thallium 201
ABCB1
: ATP-binding cassette sub-family B member 1
ABI
: ankle-brachial index
ACC
: American College of Cardiology
ACCF
: American College of Cardiology Foundation
ACCOMPLISH
: Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension
ACE
: angiotensin converting enzyme
ACIP
: Asymptomatic Cardiac Ischaemia Pilot
ACS
: acute coronary syndrome
ADA
: American Diabetes Association
ADP
: adenosine diphosphate
AHA
: American Heart Association
ARB
: angiotensin II receptor antagonist
ART
: Arterial Revascularization Trial
ASCOT
: Anglo-Scandinavian Cardiac Outcomes Trial
ASSERT
: Asymptomatic atrial fibrillation and Stroke Evaluation in pacemaker patients and the atrial fibrillation Reduction atrial pacing Trial
AV
: atrioventricular
BARI 2D
: Bypass Angioplasty Revascularization Investigation 2 Diabetes
BEAUTIFUL
: Morbidity-Mortality Evaluation of the If Inhibitor Ivabradine in Patients With Coronary Artery Disease and Left Ventricular Dysfunction
BIMA
: bilateral internal mammary artery
BMI
: body mass index
BMS
: bare metal stent
BNP
: B-type natriuretic peptide
BP
: blood pressure
b.p.m.
: beats per minute
CABG
: coronary artery bypass graft
CAD
: coronary artery disease
CAPRIE
: Clopidogrel vs. Aspirin in Patients at Risk of Ischaemic Events
CASS
: Coronary Artery Surgery Study
CCB
: calcium channel blocker
CCS
: Canadian Cardiovascular Society
CFR
: coronary flow reserve
CHARISMA
: Clopidogrel for High Atherothrombotic Risk and Ischaemic Stabilization, Management and Avoidance
CI
: confidence interval
CKD
: chronic kidney disease
CKD-EPI
: Chronic Kidney Disease Epidemiology Collaboration
CMR
: cardiac magnetic resonance
CORONARY
: The CABG Off or On Pump Revascularization Study
COURAGE
: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation
COX-1
: cyclooxygenase-1
COX-2
: cyclooxygenase-2
CPG
: Committee for Practice Guidelines
CT
: computed tomography
CTA
: computed tomography angiography
CV
: cardiovascular
CVD
: cardiovascular disease
CXR
: chest X-ray
CYP2C19*2
: cytochrome P450 2C19
CYP3A
: cytochrome P3A
CYP3A4
: cytochrome P450 3A4
CYP450
: cytochrome P450
DANAMI
: Danish trial in Acute Myocardial Infarction
DAPT
: dual antiplatelet therapy
DBP
: diastolic blood pressure
DECOPI
: Desobstruction Coronaire en Post-Infarctus
DES
: drug-eluting stents
DHP
: dihydropyridine
DSE
: dobutamine stress echocardiography
EACTS
: European Association for Cardiothoracic Surgery
EECP
: enhanced external counterpulsation
EMA
: European Medicines Agency
EASD
: European Association for the Study of Diabetes
ECG
: electrocardiogram
Echo
: echocardiogram
ED
: erectile dysfunction
EF
: ejection fraction
ESC
: European Society of Cardiology
EXCEL
: Evaluation of XIENCE PRIME or XIENCE V vs. Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization
FAME
: Fractional Flow Reserve vs. Angiography for Multivessel Evaluation
FDA
: Food & Drug Administration (USA)
FFR
: fractional flow reserve
FREEDOM
: Design of the Future Revascularization Evaluation in patients with Diabetes mellitus: Optimal management of Multivessel disease
GFR
: glomerular filtration rate
HbA1c
: glycated haemoglobin
HDL
: high density lipoprotein
HDL-C
: high density lipoprotein cholesterol
HR
: hazard ratio
HRT
: hormone replacement therapy
hs-CRP
: high-sensitivity C-reactive protein
HU
: Hounsfield units
ICA
: invasive coronary angiography
IMA
: internal mammary artery
IONA
: Impact Of Nicorandil in Angina
ISCHEMIA
: International Study of Comparative Health Effectiveness with Medical and Invasive Approaches
IVUS
: intravascular ultrasound
JSAP
: Japanese Stable Angina Pectoris
KATP
: ATP-sensitive potassium channels
LAD
: left anterior descending
LBBB
: left bundle branch block
LIMA
: Left internal mammary artery
LDL
: low density lipoprotein
LDL-C
: low density lipoprotein cholesterol
LM
: left main
LMS
: left main stem
LV
: left ventricular
LVEF
: left ventricular ejection fraction
LVH
: left ventricular hypertrophy
MACE
: major adverse cardiac events
MASS
: Medical, Angioplasty, or Surgery Study
MDRD
: Modification of Diet in Renal Disease
MERLIN
: Metabolic Efficiency with Ranolazine for Less Ischaemia in Non-ST-Elevation Acute Coronary Syndromes
MERLIN-TIMI 36
: Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST-Elevation Acute Coronary Syndromes: Thrombolysis In Myocardial Infarction
MET
: metabolic equivalents
MI
: myocardial infarction
MICRO-HOPE
: Microalbuminuria, cardiovascular and renal sub-study of the Heart Outcomes Prevention Evaluation study
MPI
: myocardial perfusion imaging
MRI
: magnetic resonance imaging
NO
: nitric oxide
NSAIDs
: non-steroidal anti-inflammatory drugs
NSTE-ACS
: non-ST-elevation acute coronary syndrome
NYHA
: New York Heart Association
OAT
: Occluded Artery Trial
OCT
: optical coherence tomography
OMT
: optimal medical therapy
PAR-1
: protease activated receptor type 1
PCI
: percutaneous coronary intervention
PDE5
: phosphodiesterase type 5
PES
: paclitaxel-eluting stents
PET
: positron emission tomography
PRECOMBAT
: Premier of Randomized Comparison of Bypass Surgery vs. Angioplasty Using Sirolimus-Eluting Stent in Patients with Left Main Coronary Artery Disease
PTP
: pre-test probability
PUFA
: polyunsaturated fatty acid
PVD
: peripheral vascular disease
QoL
: quality of life
RBBB
: right bundle branch block
REACH
: Reduction of Atherothrombosis for Continued Health
RITA-2
: Second Randomized Intervention Treatment of Angina
ROOBY
: Veterans Affairs Randomized On/Off Bypass
SAPT
: single antiplatelet therapy
SBP
: systolic blood pressure
SCAD
: stable coronary artery disease
SCORE
: Systematic Coronary Risk Evaluation
SCS
: spinal cord stimulation
SES
: sirolimus-eluting stents
SIMA
: single internal mammary artery
SPECT
: single photon emission computed tomography
STICH
: Surgical Treatment for Ischaemic Heart Failure
SWISSI II
: Swiss Interventional Study on Silent Ischaemia Type II
SYNTAX
: SYNergy between percutaneous coronary intervention with TAXus and cardiac surgery
TC
: total cholesterol
TENS
: transcutaneous electrical neural stimulation
TERISA
: Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina
TIME
: Trial of Invasive vs. Medical therapy
TIMI
: Thrombolysis In Myocardial Infarction
TMR
: transmyocardial laser revascularization
TOAT
: The Open Artery Trial
WOEST
: What is the Optimal antiplatElet and anticoagulant therapy in patients with oral anticoagulation and coronary StenTing

Guidelines summarize and evaluate all evidence available, at the time of the writing process, on a particular issue with the aim of assisting physicians in selecting the best management strategies for an individual patient with a given condition, taking into account the impact on outcome, as well …

/pdf/2013-esc-guidelines-on-the-management-of-stable-coronary-2178xukyyy.pdf

2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology.

Authors/Task Force Members: Franz-Josef Neumann* (ESC Chairperson) (Germany), Miguel Sousa-Uva* (EACTS Chairperson) (Portugal), Anders Ahlsson (Sweden), Fernando Alfonso (Spain), Adrian P. Banning (UK), Umberto Benedetto (UK), Robert A. Byrne (Germany), Jean-Philippe Collet (France), Volkmar Falk (Germany), Stuart J. Head (The Netherlands), Peter Jüni (Canada), Adnan Kastrati (Germany), Akos Koller (Hungary), Steen D. Kristensen (Denmark), Josef Niebauer (Austria), Dimitrios J. Richter (Greece), Petar M. Seferovi c (Serbia), Dirk Sibbing (Germany), Giulio G. Stefanini (Italy), Stephan Windecker (Switzerland), Rashmi Yadav (UK), Michael O. Zembala (Poland) Document Reviewers: William Wijns (ESC Review Co-ordinator) (Ireland), David Glineur (EACTS Review Co-ordinator) (Canada), Victor Aboyans (France), Stephan Achenbach (Germany), Stefan Agewall (Norway), Felicita Andreotti (Italy), Emanuele Barbato (Italy), Andreas Baumbach (UK), James Brophy (Canada), Héctor Bueno (Spain), Patrick A. Calvert (UK), Davide Capodanno (Italy), Piroze M. Davierwala

/pdf/2014-esc-eacts-guidelines-on-myocardial-revascularization-3fr5n9jz36.pdf

2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI).

Coronary artery disease (CAD) is a pathological process characterized by atherosclerotic plaque accumulation in the epicardial arteries, whether obstructive or non-obstructive. This process can be modified by lifestyle adjustments, pharmacological therapies, and invasive interventions designed to achieve disease stabilization or regression. The disease can have long, stable periods but can also become unstable at any time, typically due to an acute atherothrombotic event caused by plaque rupture or erosion. However, the disease is chronic, most often progressive, and hence serious, even in clinically apparently silent periods. The dynamic nature of the CAD process results in various clinical presentations, which can be conveniently categorized as either acute coronary syndromes (ACS) or chronic coronary syndromes (CCS). The Guidelines presented here refer to the management of patients with CCS. The natural history of CCS is illustrated in Figure 1.

/pdf/2019-esc-guidelines-for-the-diagnosis-and-management-of-5b7mv2v506.pdf

2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes.

886 diabetes mellitus, hypertension, or smoking. His only risk factor was dyslipidemia. Coronary an‐ giography revealed a triple ‐vessel disease with subtotal (90%) occlusion in the proximal por‐ tion of I marginal branch and an 80% discrete lesion in the distal portion of the left circum‐ flex artery (LCX) (FIGURE 1B). The patient was treat‐ ed successfully with the deployment of 2 drug‐ ‐eluting stents in the LCX/I marginal (bifurca‐ tion, CRE8, 3. 5 × 16 mm) and in the distal LCX (CRE8, 3.0 × 16 mm) lesions. Transthoracic echo‐ cardiography revealed normal chamber diame‐ ters and left ventricular function with preserved ejection fraction (60%). Twin B, the monozygotic twin brother of twin A, a 53‐year ‐old man, was convinced to under‐ go exercise ECG treadmill test, as he was expe‐ riencing dyspnea upon exertion. His only preva‐ lent risk factor was dyslipidemia, similarly to his brother. The exercise test yielded postive results on ECG, so he underwent coronary angiography, which revealed a single ‐vessel disease with a 95% lesion at the seventh segment of the LAD (FIGURES 1C and 1D). The right coronary artery and LCX were normal. A sirolimus ‐eluting stent was later suc‐ cessfully implanted in the LAD. Transthoracic echocardiography revealed normal chamber di‐ ameters with hypokinesis of the anterior wall and a preserved ejection fraction (50%). Little is known about angiographic findings in twin pairs with CAD. Although previous obser‐ vational studies have claimed that the location of coronary lesions is not hereditary,4 the sim‐ ilar location of stenosis in the LAD, age at first cardiac event, and risk factor profiles show con‐ cordance in this pair of identical twins. In conclusion, we suggest that when one twin presents with CAD, the second twin should be under closer medical surveillance. Coronary artery disease (CAD), the leading cause of death in Poland, originates in ear‐ ly life.1 The lack of fully satisfying treatment strategies caused researchers to look at CAD from a different angle. Consequently, it was postulated that epigenetic factors play an im‐ portant role in the early ‐life programming of adult health and diseases.1 Due to the fact that twin pairs may experience different intrau‐ terine environments, studies on monozygot‐ ic twins with discordant phenotypes are one of the most useful study designs in epigenet‐ ic epidemiology.1 The largest prospective study in a twin co‐ hort was conducted by Silventoinen et al2 and was based on pooled twin data from Denmark, Finland, and Sweden. The authors acknowledged the existence of a clear aggregation of CAD mor‐ tality in twins, and especially in monozygotic twins (genetically identical). Similarly, previ‐ ous studies have shown concordance in symp‐ toms of angina pectoris in twins.2 Subsequently, Hjelmborg et al3 indicated that studies in twin cohorts seem to be vital to ensure the represen‐ tativeness to the general population. Our case is an example of a monozygotic twin pair presenting with a similar lesion location in the left anterior descending artery (LAD) and an identical risk factor profile. Twin A, a 53‐year ‐old man, was diagnosed with non–ST ‐segment elevation acute myocar‐ dial infarction and was successfully treated with the deployment of 3 sirolimus ‐eluting stents (CRE8, 3.5 × 16 mm; CRE8, 3.0 × 21 mm; and CRE8, 2.75 × 16 mm [CID S.p.A., Saluggia, Italy]) in the proximal and medial portions of the LAD (FIGURE 1A). The patient was subsequently referred to our institute for further management. The fol‐ lowing risk factors were not present: obesity, Correspondence to: Izabela Warchoł, MD, Department of Interventional Cardiology and Cardiac Arrhythmias, Medical University of Lodz, ul. Żeromskiego 113, 90-549 Łódź, Poland, phone: +48 42 63 93 563, email: izabelaritawarchol@gmail.com Received: April 24, 2019. Revision accepted: July 23, 2019. Published online: July 25, 2019. Kardiol Pol. 2019; 77 (9): 886-887 doi:10.33963/KP.14910 Copyright by the Author(s), 2019 C L I N I C A L V I G N E T T E

/pdf/deja-vu-coronary-artery-disease-in-monozygotic-twins-1uwc35dtwm.pdf

Déjà vu: coronary artery disease in monozygotic twins.

Pacing mode in sinus node disease (SND) is one of controversies in cardiac pacing. We evaluated atrial pacing mode (AAI) in SND patients (pts). Between 1985 and 1994 AAI pacemaker was inserted in 179 pts due to symptomatic SND of varied etiology. Results The majority of pts (91.6%) were free from syncopal episodes after AAI implantation, in 15 pts (8.4%) syncopes were occasionally observed due to disturbances in pacemaker function, AVB III degrees, vaso-vagal syndrome, orthostatic hypotonia or atherosclerotic insufficiency of the cerebral circulation. In 49 (51%) out of 96 pts with brady-tachy syndrome (BTS), episodes of supraventricular tachyarrhythmia were not observed after AAI insertion and in the majority of the remaining pts the frequency of the episodes decreased significantly. Chronic atrial fibrillation developed in 5 (5.2%) pts. In some of the pts the symptoms related to chronic heart failure decreased or disappeared. A reoperation was performed in 44 (24%) pts due to electrode dislocation or fracture, atrio-ventricular conduction disturbances, an increase in pacing threshold or due to local infections. During the follow-up period 13 (7.3%) pts died of reasons unrelated to cardiac pacing therapy. Conclusion In the majority of SND pts AAI pacing mode prevents from syncopal episodes caused by sinus node disfunction. It decreases the symptoms of heart failure in SND pts and stabilizes the sinus rhythm in the majority of BTS pts. Complications accompanying AAI do not post a major threat for the pts and can be easily resolved. They should by no means discourage from AAI implantation in SND.

Advantages and Controversies Regarding Physiologic Electrostimulation of the Heart in Sinus Node Disease

Specyfika częstoskurczu komorowego w zależności od schorzenia podstawowego. Co wiemy o częstoskurczu komorowym - część III

/pdf/comment-to-article-circumferential-pulmonary-vein-rf-1fxnan09k0.pdf

Andrzej Lubiński

Papers

Déjà vu: coronary artery disease in monozygotic twins.

Advantages and Controversies Regarding Physiologic Electrostimulation of the Heart in Sinus Node Disease

Specyfika częstoskurczu komorowego w zależności od schorzenia podstawowego. Co wiemy o częstoskurczu komorowym - część III

Comment to article Circumferential pulmonary vein RF ablation in the treatment of atrial fibrillation: 3-year experience of one centre

806 Complications related to left ventricular lead implantation for permanent biventricular pacing in patients with advanced heart failure